By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Purdue Pharma L.P. (Research & Development - New Jersey) 

6 Cedar Brook Drive

Cranbury  New Jersey  08512  U.S.A.
Phone: 609-409-5123 Fax: 609-409-5799


Today, advances in technology are helping scientists reach an unprecedented understanding of human health and disease. This expansion of scientific knowledge is shaping pharmaceutical research in ways never before imagined. Scientists are using powerful and innovative tools to screen potential new drugs and to identify promising targets for treating medical conditions.

Purdue Pharma is committed to developing safe and effective medicines to treat pain and other conditions. As a science-based company, we are discovering drugs with new mechanisms of action and exploring new techniques in drug delivery to enhance the effectiveness and safety of drug therapy.

Our researchers and clinicians, based in Cranbury, New Jersey, have expertise in neurology, pharmacology, pharmaceutics, toxicology, molecular biology, combinatorial chemistry, and other disciplines. Company scientists and clinicians are collaborating to discover new weapons against pain and to develop new formulations to improve the effectiveness of existing therapies. On our own and through our collaboration with Shionogi, a leading Japanese pharmaceutical company, Purdue is engaged in pioneering work in the areas of nociceptive and neuropathic pain. The company is also expanding its expertise in extended-release drug delivery systems.

Purdue scientists are continuing to study and understand the real-world problem of abuse of prescription drugs. They are discovering new compounds to treat pain and developing formulations and delivery systems to help improve patient safety.

Key Statistics

Ownership: Private

Web Site: Purdue Pharma L.P.
Employees: 90


Company News
Purdue Pharma L.P. Release: Abuse, Addiction, And Opioid Poisoning Results In Commercially-Insured Individuals Following Introduction Of Reformulated Oxycontin (oxycodone Hcl Extended-Release Tablets) CII 3/23/2015 9:08:58 AM
Purdue Pharma L.P. Release: Hysingla™ ER (hydrocodone bitartrate) Extended-Release Tablets CII Now Available 1/26/2015 9:34:45 AM
Esteve S.A. (Laboratorios Del Dr. Esteve S.A.) Could Bank $1 Billion From Mundipharma AG, Purdue Pharma L.P. Pain Pact 1/12/2015 6:04:11 AM
FDA Approves Purdue Pharma L.P.’s Hard-to-Abuse Narcotic Painkiller 7/28/2014 7:40:59 AM
Purdue Pharma L.P., A Leading Pharmaceutical Company Extends Its Infrastructure Transformation Contract With HCL Technologies 6/18/2014 10:56:59 AM
Purdue Pharma L.P. Submits NDA For Once-Daily Hydrocodone Bitartrate Extended-Release Tablets Formulated To Incorporate Abuse-Deterrent Properties 4/30/2014 10:06:30 AM
Zogenix, Inc. (ZGNX) Falls As Rival Purdue Pharma L.P. Announces Positive Phase 3 Trial Of Abuse-Resistant Pill 3/12/2014 7:14:26 AM
Purdue Pharma L.P. Names Mark Timney President And Chief Executive Officer 1/27/2014 6:44:41 AM
Purdue Pharma L.P. Announces Resolution Of OxyContin® (Oxycodone HCl Controlled-Release) Tablets CII Patent Lawsuit With IMPAX Laboratories, Inc. (IPXL) 12/3/2013 11:46:13 AM
FDA Accepts For Review Purdue Pharma L.P.'s New Drug Application For Targiniq™ ER (oxycodone HCl/naloxone HCL Controlled-Release) Tablets CII 11/26/2013 8:49:24 AM